Research has now shown that mutations in KEAP1 and NFE2L2 are often associated with late-stage metastatic disease [230], with stage-4 cancer patients showing higher NRF2 activity than stage-3 patients [231]. This evidence concerns the gene NFE2L2 and cancer.